- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Brinzamide intermediate
【Catalogue Number】AP0901
【CAS #】160982-16-1
【Molecular formula】C6H6ClNO3S2
[Product Introduction] (S)-6-chloro-3,4-dihydro-2H-thiophene [3,2-E]-1,2-thiazin-4-ol 1,1-dioxide, English name Is (S)-3,4-Dihydro-6-chloro-4-hydroxy-4H-thieno[3,2-e]-1,2-thiazine-1,1-dioxide, and the American Chemical Abstracts Registry Number is cas160982 16-1.
Brinzamide intermediate
(S)-3,4-Dihydro-6-chloro-4-hydroxy-4H-thieno[3,2-e]-1,2-thiazine-
1,1-dioxide
CAS 160982-16-1
Alternate name Brinzamide intermediate
Catalog number AP0901
CAS # 160982-16-1
Molecular formula C6H6ClNO3S2
Molecular weight 239.7
Structural formula
Product introduction
CAS 160982-16-1 (S) -6-chloro-3,4-dihydro-2H-thiophene [3,2-E] -1,2-thiazin-4-ol 1,1-dioxide, The English name is (S) -3,4-Dihydro-6-chloro-4-hydroxy-4H-thieno [3,2-e] -1,2-thiazine-1,1-dioxide. cas160982-16-1.
This product (cas 160982-16-1) is an intermediate of brinzolamide. Brinzolamide can be used to treat primary and secondary open-angle glaucoma and ocular hypertension. It can also be used to prevent the increase of intraocular pressure after laser surgery. Can be used as a single treatment drug for patients who are ineffective against β-blockers, or have contraindications to use, or as a synergistic treatment for β-blockers.
VIWIT 沪ICP备12014533号-1
